Sacituzumab govitecan is a new drug that represents an antibody-drug conjugate targeting the Trop-2 antigen found on the surface of breast cancer cells[1]. In a phase 3 randomized clinical trial, it was compared with traditional chemotherapy in patients with advanced triple-negative breast cancer[1]. Patients treated with sacituzumab govitecan achieved a median progression-free period of 5.6 months compared to 1.7 months in the chemotherapy group[1]. The new combination of sacituzumab govitecan with pembrolizumab (immunotherapy) showed even better results with an average of more than eleven months without disease progression[2]. The objective response rate to treatment in the new combination reached 60 percent[2]. Patients treated with the new combination tolerated treatment better and discontinued treatment less often due to side effects[2]. The most common side effects of sacituzumab govitecan were bone marrow suppression and diarrhea[1].